Evicenter
Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) in Pneumococcal disease prevention in adults
Manufacturer
Wyeth Pharmaceutical Division of Wyeth Holdings LLC
Prescribing information
Prevnar 20 (opens in a new tab)
Questions
21
Last updated

All questions

Indication: Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) in pneumococcal disease prevention in adults

6 questions · 5 sources

Indication

What is Prevnar 20 approved for in adults?

Note: The label also lists an otitis media indication for children 6 weeks through 5 years of age, which is outside the adult scope of this page.

Which Prevnar 20 pneumonia serotypes are under accelerated approval?

Eligibility

Prevnar 20 and diabetes: what are the pneumococcal vaccination recommendations?

Note: The ADA statement concerns pneumococcal vaccination in general; the page cites the ADA Standards of Care in Diabetes 2025. The Prevnar 20 line cites the ACIP recommendations published in MMWR in 2025, which are for pneumococcal conjugate vaccination.

Prevnar 20 and COPD: what are the pneumococcal vaccination recommendations?

Note: The ALA statement concerns pneumococcal vaccination of patients at increased risk of pneumococcal pneumonia in general; the page cites the ALA web page Preventing pneumonia, updated June 3, 2025. The Prevnar 20 line cites the ACIP recommendations published in MMWR in 2025, which are for pneumococcal conjugate vaccination.

Prevnar 20 and asthma: what are the pneumococcal vaccination recommendations?

Note: The AAFA statement concerns pneumococcal vaccination in general; the page cites the AAFA vaccine recommendations page, reviewed February 2017. The Prevnar 20 line cites the ACIP recommendations published in MMWR in 2025, which are for pneumococcal conjugate vaccination.

Prevnar 20 and chronic heart disease: what are the pneumococcal vaccination recommendations?

Note: The 2022 AHA/ACC/HFSA guideline statement concerns adults with heart failure and vaccination against respiratory illnesses in general. The Prevnar 20 line cites the ACIP recommendations published in MMWR in 2025, which are for pneumococcal conjugate vaccination.